Advasa Announces Proposed Share Forfeiture by Largest Stockholder
Advasa Holdings, Inc. has announced a proposal regarding the forfeiture of shares held by its largest stockholder.
Stocks · News reference
Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
US stock futures mixed, Intuit shares dip 11.7% after reporting Q4 revenue of $4.35B and adjusted earnings of $4.03/share. FY27 guidance below estimates. Other stocks moving lower in pre-market trading.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Advasa Holdings, Inc. (ADBT)
Filed: 2026-10-22 AccNo: 0001493152-26-048122 Size: 228 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Advasa Holdings Board Adopts Dividend Policy Targeting Annual Cash Dividend Payout Ratio Of 50% For Its Common Stock, Beginning With Fiscal Year Ending March 31, 2027
Advasa Holdings, Inc. (NASDAQ:ADBT) ("ADVASA" or the "Company"), a fintech payment holding company delivering Earned Wage Access ("EWA") and financial infrastructure solutions, today announced
Shares of enterprise software companies are trading higher amid an investor rotation from highly leveraged AI-exposed names into the legacy tech services sector. Fears of persistently high inflation and interest rates may increase the appeal of the industry's proven business models.
BioCryst to Report Third Quarter 2026 Financial Results on November 4
BioCryst Pharmaceuticals, Inc. announced it will release its financial results for the third quarter of 2026 on November 4, 2026, followed by a conference call and webcast.
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets
BioCryst Pharmaceuticals received U.S. FDA approval for its new 150 mg oral pellet formulation of ORLADEYO (berotralstat) for the prevention of hereditary angioedema (HAE) attacks.